Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics has announced that the first patient has been dosed in a Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis. This marks a significant step in the development of the drug.
July 06, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics' announcement of the first patient being dosed in a Phase 2 study of Barzolvolimab could potentially boost investor confidence and have a positive impact on the company's stock.
The announcement of the first patient being dosed in a Phase 2 study is a significant milestone in the development of a drug. This news could potentially boost investor confidence in Celldex Therapeutics and have a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100